BOSTON: Biotechnology company Biogen Idec has released data from its Alzheimer’s disease drug trial, which reveals that the drug slows down the neurodegenerative disease.
The Cambridge-based firm specialized in developing, discovering and delivering therapies for the treatment of autoimmune, neurodegenerative and hematologic diseases to patients across the world.
The company has released trial results, which suggests that the company’s experimental drug reduced the mental deterioration of a small number of patients who showed early symptoms of Alzheimer’s disease…